Although new antibiotics are very much needed, they will only be most effective if they’re used sparingly — for the most critical of cases. This presents serious economic challenges to developing antibiotics.
The development and ultimate approval of tecovirimat for the antiviral treatment of smallpox, a disease that has been eradicated from the world for nearly 40 years, required a unique regulatory approach based on the US Food and Drug Administration's Animal Rule.
This year’s event will gather leaders from pharmaceutical companies, academia and the wider scientific community together with regulatory agencies and public-private partnerships, to discuss the growing threat of antibiotic resistance.
Using computer modelling, researchers were able to identify new drugs by building a reliable replica of the bacterial protein and then working out what the best orientation is for the drug to fit in the bacterial protein.
The aim of the conference is to harness cross-disciplinary and cross-disease learning to accelerate drug discovery and reduce drug candidate attrition rates for infectious diseases affecting low and middle income countries. Conference attendees will take home new ideas and technologies which have been demonstrated to work; applying them to diseases where challenges to drug discovery are hampering progress.
Accepting that antibiotics are infrastructure would change our relationship to the drugs, forcing us to recognize that medicine requires long-term planning.
It can be a challenge for the government to convince pharmaceutical companies to develop drugs for the US national stockpile that are not commercially viable.
Biomedical research follows a predictable pattern of growth and maturation, and that few new medicines are successfully developed before this research passes a critical established point.
The conference agenda is a mix of presentations, panel discussions, and short technology presentations that will cover a wide range of strategies for successful drug discovery.